Circulating levels of LL-37 based on antibody shared epitope and vitamin D status
| Anti-CCP negative | 10.9 (4.1, 16.7) 0–4050.2 | P=0.001 |
| Anti-CCP positive | 17.1 (8.7, 43.3) 0–2303.1 | |
| RF negative | 10.4 (3.8, 14.3) 0–4050.2 | P=0.001 |
| RF positive | 16.6 (8.2, 30.5) 0–2303.1 | |
| Number of autoantibodies | ||
| RF and anti-CCP negative | 10.4 (3.8, 13.9) 0–4050.2 | P<0.0001 |
| RF or anti-CCP positive | 10.9 (5.4, 23.4) 0–1073.4 | |
| RF and anti-CCP positive | 17.4 (9.24, 47.7) 0–2303.1 | |
| Shared epitope positive | 11.8 (6.1, 23.7) 0–2303 | P=0.5 |
| Shared epitope negative | 10.9 (4.1, 21.5) 0–4050.2 | |
| 25(OH)D <25 nmol/L (deficient) | 12.2 (7.2, 25.3) 0–4050.2 | P=0.08 |
| 25(OH)D >25 nmol/L (adequate) | 10.9 (4.1, 19.9) 0–1469.2 | |
| Smoking status | ||
| Never smoked | 11.2 (4.9, 21.9)0.1–4050.2 | P=0.4 |
| Quit smoking | 11.9 (7.2, 21.8) 0–1469.2 | |
| Current smoking | 14.2 (8.6, 47.9) 0–2303.1 | |
| Vit D receptor polymorphism | ||
| Fokl | 10.6 (5.3, 24.7) 0–2303 | P=1.0 |
| CC | 11.9 (5.0, 21.6) 0.1–4050.1 | |
| CT | 12.3 (6.8, 19.4) 0–1469.2 | |
| TT | ||
| Bsm1 | 11.6 (8.5, 17.1) 0.2–550.8 | P=0.3 |
| TT | 13.4 (6.5, 23.6) 0–4050.2 | |
| CT | 9.6 (4.1, 21.0) 0–1469.2 | |
| CC | ||
| Apa1 | 11.6 (7.4, 17.1) 0.23–550.8 | P=1.0 |
| TT | 11.6 (5.0, 26.0) 0–4050.2 | |
| GT | 11.9 (4.9, 22.3) 0–1469 | |
| GG | ||
| Taq1 | 10.2 (4.7, 22.0) 0–1469.2 | P=0.8 |
| TT | 11.9 (5.5, 23.9) 0–4050.2 | |
| TC | 12.5 (8.8, 17.3) 0.2–550.8 | |
| CC |
Median (25th, 75th quartile) (range) reported. Statistical significance determined using Man-Whitney U non-parametric two group comparison or Kruskal-Wallis test for three group comparison.
CCP, cyclical citrullinated peptide; RF, rheumatoid factor.